Bioxyne Ltd: A Year of Growth and Expansion

In a recent announcement, Bioxyne Limited, a biotechnology company specializing in chronic obstructive pulmonary disease (COPD) products, has provided an optimistic outlook for the fiscal year 2026. The company, listed on the ASX All Markets under the ticker BXN, has set ambitious revenue and EBITDA targets, reflecting its strategic growth initiatives and market expansion efforts.

FY2026 Guidance: A Promising Horizon

Bioxyne has projected a revenue range of $65 million to $75 million for FY2026, with EBITDA expected to fall between $11.5 million and $13.5 million. This guidance underscores the company’s confidence in its growth trajectory, driven by several key factors:

• Expansion in Australia: The company is capitalizing on its Australian medical cannabis business, with new contract wins and increased order volumes from existing clients.
• International Ventures: A significant milestone is the entry into the German market, marked by a maiden contract worth $5.8 million. The first shipment to Germany is set for September 2025, with a second shipment planned for November 2025, increasing the initial delivery from 580kg to 1,550kg.
• Manufacturing and Supply Contracts: Bioxyne has secured new contracts with large Australian distributors and clinics, further solidifying its domestic market presence.

Reflecting on FY2025: A Year of Transformation

The preliminary final report for the year ended 30 June 2025 highlights a remarkable turnaround for Bioxyne. The company reported a 215% increase in revenue from ordinary activities, rising from $9.65 million in FY2024 to $30.45 million in FY2025. This growth is a testament to the company’s strategic initiatives and market responsiveness.

Profitability has also seen a dramatic improvement. The profit from ordinary activities after tax attributable to members surged from a loss of $13.33 million in FY2024 to $4.90 million in FY2025. This turnaround is indicative of Bioxyne’s effective cost management and operational efficiencies.

Financial Health and Future Prospects

Bioxyne’s net tangible assets per issued security have increased by 47%, from 15 cents in FY2024 to 22 cents in FY2025. This improvement reflects the company’s strengthened financial position and its ability to generate shareholder value.

Despite the positive financial performance, Bioxyne has not proposed any dividends for FY2025, focusing instead on reinvesting profits to fuel further growth and expansion.

Looking Ahead

Bioxyne is well-positioned for continued growth in FY2026, with its strategic focus on expanding its business in Australia and entering new high-growth markets such as the UK, Germany, and other EU countries. The company’s success in contract manufacturing services, particularly in pastilles, flower packing, and liquids, is expected to remain a key driver of growth.

As Bioxyne embarks on this exciting phase of expansion, stakeholders can look forward to a company that is not only growing its market presence but also contributing to the advancement of biotechnology solutions for chronic obstructive pulmonary disease.

For more information, stakeholders are encouraged to refer to the detailed financials and forward-looking statements provided in Bioxyne’s announcements.